Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Understand the key factors for determining when to sell stocks and buy bonds to optimize your investment strategy.
28,656 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
A new institutional stake in Howard Hughes Holdings suggests rising confidence in the stock. With 140,268 shares boug...
Nvidia could be headed toward a $300 stock price as AI demand, margins, and strategic bets align. This article breaks...
In 2025, rare earths drew intense attention as prices and equities raced higher. The rally cooled quickly, leaving in...
SpaceX plans to push Starship through another high-stakes test flight. Here’s what investors should watch, how it cou...
Institutional investors are loading up on two beaten-down software giants as AI infrastructure demand remains solid a...
A hidden AI stock is drawing quiet attention. This article breaks down why investors are eyeing it before its next ea...
Debt service now approaches $1 trillion annually as the interest on the $38.8 trillion national debt climbs, squeezin...
In a volatile market, a straightforward approach is gaining traction: carve out an income sleeve that pays a steady $...
A leading economist warns that renewed hostilities with Iran could trigger a butterfly effect in global markets, keep...
MicroStrategy pauses BTC purchases, buys 1.5B face value of 0% notes due 2029 for about $1.38B, and shifts toward a b...
High‑net‑worth investors are leaning on tax‑aware planning this year. The playbook centers on advisor guidance, tax‑e...